Our portfolio

To date, CEPI has established multiple partnership agreements, reflecting a potential investment of up to $370 million. Through these collaborations, we're supporting the development of a wide range of vaccine candidates.

We also have number of additional partnerships under negotiation. These partnership agreements represent the start of CEPI’s product development portfolio. See below current details of our vaccine portfolio.

Filter by:

PRODUCT DEVELOPERS

All
IDT Biologika
Imperial College London
Inovio Pharmaceuticals
International AIDS Vaccine Initiative
Janssen Vaccines & University of Oxford
Profectus Biosciences, Emergent Biosolutions & PATH
Themis Bioscience
University of Queensland

DISEASE

All
Inflluenza virus
Lassa virus
Marburg virus
MERS coronavirus
Nipah virus
Rabies virus
Respiratory syncytial virus

VACCINE TYPE

All
ASPIRE (DNA vaccine)
Measles vector
Molecular clamp platform
Recombinant Modified Vaccinia Ankara
Replication-deficient simian adenoviral vaccine vector, ChAdOx1
rVSVNC4ΔG
rVSVΔG
saRNA platform
VesiculoVax

PHASE

All
Phase 1
Phase 2
Preclinical

Filter by product developers:

All
IDT Biologika
Imperial College London
Inovio Pharmaceuticals
International AIDS Vaccine Initiative
Janssen Vaccines & University of Oxford
Profectus Biosciences, Emergent Biosolutions & PATH
Themis Bioscience
University of Queensland

Filter by disease:

All
Inflluenza virus
Lassa virus
Marburg virus
MERS coronavirus
Nipah virus
Rabies virus
Respiratory syncytial virus

Filter by vaccine type:

All
ASPIRE (DNA vaccine)
Measles vector
Molecular clamp platform
Recombinant Modified Vaccinia Ankara
Replication-deficient simian adenoviral vaccine vector, ChAdOx1
rVSVNC4ΔG
rVSVΔG
saRNA platform
VesiculoVax

Filter by phase:

All
Phase 1
Phase 2
Preclinical

Clinical Trial Registry No.

CEPI Funding (USD)

N/A

No result